

H-P Hartung

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2689009/h-p-hartung-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

295
papers

30,281
citations

59
h-index

172
g-index

316
ext. papers

35,330
ext. citations

8.9
avg, IF

6.77
L-index

#	Paper	IF	Citations
295	Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.. <i>Journal of Neurology</i> , 2022 , 1	5.5	0
294	CNS Involvement in Chronic Inflammatory Demyelinating Polyneuropathy: Subtle Retinal Changes in Optical Coherence Tomography. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	1
293	Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy.. <i>Brain</i> , 2022 ,	11.2	2
292	Body mass index as a predictor of MS activity and progression among participants in BENEFIT.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211061861	5	1
291	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 57, 103356	4	2
290	Analysis of Relapse by Inflammatory Rasch-built Overall Disability Scale Status in the PATH Study of Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy.. <i>Journal of the Peripheral Nervous System</i> , 2022 ,	4.7	
289	Eculizumab versus rituximab in generalised myasthenia gravis.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 ,	5.5	1
288	Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	3
287	Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.. <i>Neurotherapeutics</i> , 2022 , 1	6.4	3
286	Vaccination and immunotherapies in neuroimmunological diseases.. <i>Nature Reviews Neurology</i> , 2022 ,	15	3
285	The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies.. <i>Neurotherapeutics</i> , 2022 , 1	6.4	2
284	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	7
283	Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 ,	5.5	2
282	Tissue donations for multiple sclerosis research: current state and suggestions for improvement.. <i>Brain Communications</i> , 2022 , 4, fcac094	4.5	0
281	The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.. <i>Journal of Neurology</i> , 2022 , 1	5.5	1
280	031 Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 , 93, A23.1-A23	5.5	
279	Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2021 , 268, 2379-2389	5.5	15

278	Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population.. <i>Frontiers in Immunology</i> , 2021 , 12, 794075	8.4	
277	Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	14
276	Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	12
275	Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology. <i>CNS Drugs</i> , 2021 , 35, 1173-1188	6.7	3
274	CSF Findings in Acute NMDAR and LGI1 Antibody-Associated Autoimmune Encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
273	Relapse-independent multiple sclerosis progression under natalizumab. <i>Brain Communications</i> , 2021 , 3, fcab229	4.5	1
272	Semi-Automated Live Tracking of Microglial Activation in CX3CR1 Mice During Experimental Autoimmune Encephalomyelitis by Confocal Scanning Laser Ophthalmoscopy. <i>Frontiers in Immunology</i> , 2021 , 12, 761776	8.4	0
271	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	17
270	Consequences of COVID-19 pandemic lockdown on emergency and stroke care in a German tertiary stroke center. <i>Neurological Research and Practice</i> , 2021 , 3, 21	3.2	5
269	Neuroprotective Properties of 4-Aminopyridine. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	4
268	Identification of novel myelin repair drugs by modulation of oligodendroglial differentiation competence. <i>EBioMedicine</i> , 2021 , 65, 103276	8.8	7
267	Disability Outcomes in the N-MOMentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	6
266	Corneal confocal microscopy differentiates inflammatory from diabetic neuropathy. <i>Journal of Neuroinflammation</i> , 2021 , 18, 89	10.1	4
265	Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 49, 102695	4	4
264	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. <i>Neurology</i> , 2021 , 97, 68-79	6.5	19
263	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. <i>Journal of Neurology</i> , 2021 , 268, 3961-3968	5.5	26
262	Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-Making. <i>Annals of Neurology</i> , 2021 , 89, 1084-1087	9.4	
261	Association of Retinal Layer Thickness With Cognition in Patients With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	5

260	Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , 2021 , 34, 598-603	7.1	6
259	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211024997	5	13
258	Type O blood group associates with higher anti-JC polyomavirus antibody levels. <i>Brain and Behavior</i> , 2021 , 11, e2298	3.4	1
257	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 479-482	5	2
256	Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) study. <i>Clinical Neurophysiology</i> , 2021 , 132, 226-231	4.3	1
255	Role of B Cells in Multiple Sclerosis and Related Disorders. <i>Annals of Neurology</i> , 2021 , 89, 13-23	9.4	38
254	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 48, 102673	4	3
253	Long-term adherence and response to botulinum toxin in different indications. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 15-28	5.3	4
252	Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211039648	6.6	13
251	Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211019598	6.6	3
250	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2052-2061	5	4
249	Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 839-850	4.5	1
248	Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 1033-1043	5.5	9
247	Microglia contributes to remyelination in cerebral but not spinal cord ischemia. <i>Glia</i> , 2021 , 69, 2739-2751		0
246	Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk. <i>Neurotherapeutics</i> , 2021 , 18, 1654-1656	6.4	
245	Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. <i>Clinical Neurophysiology</i> , 2021 , 132, 2184-2190	4.3	0
244	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. <i>EBioMedicine</i> , 2020 , 56, 102807	8.8	30
243	Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	14

242	Merits and culprits of immunotherapies for neurological diseases in times of COVID-19. <i>EBioMedicine</i> , 2020 , 56, 102822	8.8	11
241	Retinal Changes After Posterior Cerebral Artery Infarctions Display Different Patterns of the Nasal and Temporal Sector in a Case Series. <i>Frontiers in Neurology</i> , 2020 , 11, 508	4.1	1
240	Old and new breakthroughs in neuromyelitis optica. <i>Lancet Neurology, The</i> , 2020 , 19, 280-281	24.1	7
239	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. <i>Neurology</i> , 2020 , 95, e1027-e1040	6.5	11
238	4-Aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect - Commentary. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1312-1314	5	0
237	Capillary microscopy in Europeans with idiopathic Moyamoya angiopathy. <i>Microcirculation</i> , 2020 , 27, e12616	2.9	1
236	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. <i>Neurology</i> , 2020 , 94, e407-e418	6.5	23
235	Cryptococcal meningoencephalitis in an IgG-deficient patient with multiple sclerosis on fingolimod therapy for more than five years - case report. <i>BMC Neurology</i> , 2020 , 20, 158	3.1	10
234	Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis. <i>Neurology</i> , 2020 , 94, e2373-e2383	6.5	30
233	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020 , 17, e1003348	11.6	13
232	COVID-19 and management of neuroimmunological disorders. <i>Nature Reviews Neurology</i> , 2020 , 16, 347-348		23
231	Heterogeneous fate choice of genetically modulated adult neural stem cells in gray and white matter of the central nervous system. <i>Glia</i> , 2020 , 68, 393-406	9	3
230	Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. <i>Trends in Molecular Medicine</i> , 2020 , 26, 296-310	11.5	82
229	NK cell markers predict the efficacy of IV immunoglobulins in CIDP. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	1
228	Serum neurofilament light chain: No clear relation to cognition and neuropsychiatric symptoms in stable MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	10
227	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology, The</i> , 2020 , 19, 988-997	24.1	28
226	Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102492	4	8
225	Neurological manifestations of severe acute respiratory syndrome coronavirus 2-a controversy gone viral? <i>Brain Communications</i> , 2020 , 2, fcaa149	4.5	4

224	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review. <i>Journal of the Peripheral Nervous System</i> , 2020 , 25, 230-237	4.7	10
223	Prolonged Neuropsychological Deficits, Central Nervous System Involvement, and Brain Stem Affection After COVID-19-A Case Series. <i>Frontiers in Neurology</i> , 2020 , 11, 574004	4.1	9
222	Comparison of different optomotor response readouts for visual testing in experimental autoimmune encephalomyelitis-optic neuritis. <i>Journal of Neuroinflammation</i> , 2020 , 17, 216	10.1	4
221	Corneal Confocal Microscopy Demonstrates Corneal Nerve Loss in Patients With Trigeminal Neuralgia. <i>Frontiers in Neurology</i> , 2020 , 11, 661	4.1	3
220	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. <i>Brain</i> , 2020 , 143, 2637-2652	11.2	22
219	Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , 2020 , 19, 998-1009	24.1	38
218	Retinal layers and visual conductivity changes in a case series of microangiopathic ischemic stroke patients. <i>BMC Neurology</i> , 2020 , 20, 333	3.1	1
217	Case Report: A Case of Severe Clinical Deterioration in a Patient With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020 , 11, 782	4.1	2
216	Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. <i>Journal of Neurology</i> , 2020 , 267, 308-316	5.5	9
215	Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 113-121	5.5	23
214	Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. <i>European Journal of Neurology</i> , 2020 , 27, 196-203	6	5
213	Meeting report: "Human endogenous retroviruses: HERVs or transposable elements in autoimmune, chronic inflammatory and degenerative diseases or cancer", Lyon, France, november 5th and 6th 2019 - an MS scientist's digest. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 42, 102068	4	1
212	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. <i>Brain</i> , 2020 , 143, 1127-1142	11.2	17
211	Alemtizumab: Rare serious adverse events of a high-efficacy drug. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 737-740	5	11
210	Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT. <i>Neurology</i> , 2020 , 94, e1950-e1960	6.5	10
209	Neuroprotective Properties of Dimethyl Fumarate Measured by Optical Coherence Tomography in Non-inflammatory Animal Models. <i>Frontiers in Neurology</i> , 2020 , 11, 601628	4.1	2
208	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet, The</i> , 2019 , 394, 1352-1363	4.0	247
207	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology, The</i> , 2019 , 18, 1009-1020	24.1	96

206	The dark side of the moon: looking beyond beneficial effects of cannabis use in multiple sclerosis. <i>Brain</i> , 2019 , 142, 2552-2555	11.2	3
205	Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e590	9.1	23
204	Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. <i>Neurology</i> , 2019 , 93, e1778-e1786	6.5	22
203	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology</i> , 2019 , 18, 1021-1033	24.1	98
202	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. <i>Journal of the Peripheral Nervous System</i> , 2019 , 24, 48-55	4.7	12
201	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. <i>Journal of the Peripheral Nervous System</i> , 2019 , 24, 72-79	4.7	11
200	pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 15216-15225	11.5	45
199	Clinical trials in multiple sclerosis: potential future trial designs. <i>Therapeutic Advances in Neurological Disorders</i> , 2019 , 12, 1756286419847095	6.6	6
198	Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1273-1288	5	23
197	CSI: Multiple sclerosis. Tracing optic nerve involvement by standardized optical coherence tomography. <i>Annals of Neurology</i> , 2019 , 85, 615-617	9.4	2
196	Using Optical Coherence Tomography and Optokinetic Response As Structural and Functional Visual System Readouts in Mice and Rats. <i>Journal of Visualized Experiments</i> , 2019 ,	1.6	8
195	Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients. <i>Journal of Neurology</i> , 2019 , 266, 1421-1428	5.5	18
194	Endovascular Thrombectomy as a Means to Improve Survival in Acute Ischemic Stroke: A Meta-analysis. <i>JAMA Neurology</i> , 2019 , 76, 850-854	17.2	19
193	Regulation of sirtuin expression in autoimmune neuroinflammation: Induction of SIRT1 in oligodendrocyte progenitor cells. <i>Neuroscience Letters</i> , 2019 , 704, 116-125	3.3	9
192	Misdiagnoses and delay of diagnoses in Moyamoya angiopathy-a large Caucasian case series. <i>Journal of Neurology</i> , 2019 , 266, 1153-1159	5.5	18
191	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1255-1262	5	24
190	The Molecular Basis for Remyelination Failure in Multiple Sclerosis. <i>Cells</i> , 2019 , 8,	7.9	34
189	Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. <i>BMC Neurology</i> , 2019 , 19, 190	3.1	8

188	An unmet clinical need: roads to remyelination in MS. <i>Neurological Research and Practice</i> , 2019 , 1, 21	3.2	9
187	Drug Treatment of Clinically Isolated Syndrome. <i>CNS Drugs</i> , 2019 , 33, 659-676	6.7	6
186	Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 36, 101335	4	4
185	No Alteration of Optical Coherence Tomography and Multifocal Visual Evoked Potentials in Eyes With Symptomatic Carotid Artery Disease. <i>Frontiers in Neurology</i> , 2019 , 10, 741	4.1	2
184	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , 2019 , 18, 845-856	24.1	56
183	Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases. <i>Acta Neurologica Scandinavica</i> , 2019 , 140, 290-295	3.8	4
182	Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis. <i>Journal of Neuroinflammation</i> , 2019 , 16, 203	10.1	15
181	Meningitis gone viral: description of the echovirus wave 2013 in Germany. <i>BMC Infectious Diseases</i> , 2019 , 19, 1010	4	6
180	Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2019 , 32, 305-312	7.1	33
179	Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. <i>Current Opinion in Neurology</i> , 2019 , 32, 365-377	7.1	50
178	Remyelination in multiple sclerosis: from concept to clinical trials. <i>Current Opinion in Neurology</i> , 2019 , 32, 378-384	7.1	16
177	Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change. <i>Current Opinion in Neurology</i> , 2019 , 32, 327-337	7.1	17
176	Secretome analysis of nerve repair mediating Schwann cells reveals Smad-dependent trophism. <i>FASEB Journal</i> , 2019 , 33, 4703-4715	0.9	16
175	Monoclonal Antibodies for Multiple Sclerosis: An Update. <i>BioDrugs</i> , 2019 , 33, 61-78	7.9	12
174	Managing Risks with Immune Therapies in Multiple Sclerosis. <i>Drug Safety</i> , 2019 , 42, 633-647	5.1	11
173	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019 , 326, 19-27	3.5	9
172	High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. <i>Neurology</i> , 2019 , 92, e48-e54	6.5	55
171	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1605-1617	5	46

170	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 565-573	5	4
169	Nimodipine confers clinical improvement in two models of experimental autoimmune encephalomyelitis. <i>Journal of Neurochemistry</i> , 2018 , 146, 86	6	18
168	A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. <i>Journal of the Peripheral Nervous System</i> , 2018 , 23, 108-114	4.7	13
167	ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 696-700	5	4
166	Acute exacerbations after decades of non-active chronic multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1265-1266	5	1
165	ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , 2018 , 25, 215-237	6	96
164	Teriflunomide promotes oligodendroglial differentiation and myelination. <i>Journal of Neuroinflammation</i> , 2018 , 15, 76	10.1	20
163	Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model. <i>Journal of Neuroinflammation</i> , 2018 , 15, 71	10.1	24
162	Case of alopecia universalis associated with alemtuzumab treatment in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e454	9.1	5
161	Cerebrospinal fluid findings in reversible cerebral vasoconstriction syndrome: a way to differentiate from cerebral vasculitis?. <i>Clinical and Experimental Immunology</i> , 2018 , 193, 341-345	6.2	8
160	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018 , 4, 2055217318760642	2	19
159	Human Endogenous Retroviruses in Neurological Diseases. <i>Trends in Molecular Medicine</i> , 2018 , 24, 379-394.5	11.5	127
158	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology, The</i> , 2018 , 17, 405-415	24.1	150
157	Human mesenchymal factors induce rat hippocampal- and human neural stem cell dependent oligodendrogenesis. <i>Glia</i> , 2018 , 66, 145-160	9	18
156	Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. <i>Lancet Neurology, The</i> , 2018 , 17, 689-698	24.1	34
155	Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond. <i>CNS Drugs</i> , 2018 , 32, 637-651	6.7	9
154	Moyamoya angiopathy: early postoperative course within 3 months after STA-MCA-bypass surgery in Europe-a retrospective analysis of 64 procedures. <i>Journal of Neurology</i> , 2018 , 265, 2370-2378	5.5	9
153	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology, The</i> , 2018 , 17, 35-46	24.1	146

152	Late age onset of amyotrophic lateral sclerosis is often not considered in elderly people. <i>Acta Neurologica Scandinavica</i> , 2018 , 137, 329-334	3.8	5
151	Regional variation of Guillain-Barré syndrome. <i>Brain</i> , 2018 , 141, 2866-2877	11.2	96
150	Immune-mediated neuropathies. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 31	51.1	47
149	Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e504	9.1	111
148	Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1776-1778	5	13
147	Efficacy of STA-MCA bypass surgery in moyamoya angiopathy: long-term follow-up of the Caucasian Krupp Hospital cohort with 81 procedures. <i>Journal of Neurology</i> , 2018 , 265, 2425-2433	5.5	18
146	The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 94-105	5	56
145	Dimethyl fumarate accelerates peripheral nerve regeneration via activation of the anti-inflammatory and cytoprotective Nrf2/HO-1 signaling pathway. <i>Acta Neuropathologica</i> , 2017 , 133, 489-491	14.3	12
144	International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. <i>Journal of the Peripheral Nervous System</i> , 2017 , 22, 68-76	4.7	55
143	Coronary angiography as a rare cause for incomplete anterior spinal artery syndrome. <i>Journal of Neurology</i> , 2017 , 264, 799-801	5.5	
142	Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 1092-1094	5.5	12
141	Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: "Second International Workshop on Human Endogenous Retroviruses and Disease", Washington DC, March 13th and 14th 2017. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 15, 18-22	4	4
140	Sodium intake and multiple sclerosis activity and progression in BENEFIT. <i>Annals of Neurology</i> , 2017 , 82, 20-29	9.4	50
139	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 639-647	5.5	88
138	Iron-sulfur glutaredoxin 2 protects oligodendrocytes against damage induced by nitric oxide release from activated microglia. <i>Glia</i> , 2017 , 65, 1521-1534	9	26
137	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017 , 376, 221-234	59.2	858
136	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017 , 376, 209-220	59.2	880
135	The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017 , 3, 2055217317732802	2	17

134	Whole-body positional manipulators for ocular imaging of anaesthetised mice and rats: a do-it-yourself guide. <i>BMJ Open Ophthalmology</i> , 2017 , 1, e000008	3.2	8
133	Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients-A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	9
132	Safety of bridging antiplatelet therapy with the gpIIb-IIIa inhibitor tirofiban after emergency stenting in stroke. <i>PLoS ONE</i> , 2017 , 12, e0190218	3.7	18
131	Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. <i>Neurology</i> , 2017 , 89, 1107-1116	6.5	139
130	Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. <i>Neurology</i> , 2017 , 89, 1117-1126	6.5	175
129	Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. <i>Drugs</i> , 2017 , 77, 1755-1768	12.1	33
128	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. <i>Neurology</i> , 2017 , 89, 1584-1593	6.5	42
127	CIDP and other inflammatory neuropathies in diabetes - diagnosis and management. <i>Nature Reviews Neurology</i> , 2017 , 13, 599-611	15	53
126	Fulminant intramedullary spinal cord sarcoidosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 18, 47-48	4	2
125	Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension. <i>Journal of Neurology</i> , 2017 , 264, 1370-1380	5.5	36
124	Infectious risk stratification in multiple sclerosis patients receiving immunotherapy. <i>Annals of Clinical and Translational Neurology</i> , 2017 , 4, 909-914	5.3	7
123	Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta. <i>Frontiers in Neurology</i> , 2017 , 8, 305	4.1	6
122	Outcome and Treatment Effects in Stroke Associated with Acute Cervical ICA Occlusion. <i>PLoS ONE</i> , 2017 , 12, e0170247	3.7	19
121	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. <i>PLoS ONE</i> , 2017 , 12, e0170395	3.7	27
120	Downregulation of monocytic differentiation via modulation of CD147 by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. <i>PLoS ONE</i> , 2017 , 12, e0189701	3.7	21
119	Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 468-75	5.5	109
118	Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab. <i>BMC Neurology</i> , 2016 , 16, 98	3.1	9
117	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β 1a in MS. <i>Neurology</i> , 2016 , 87, 1464-1472	6.5	21

116	Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. <i>Journal of Neuroinflammation</i> , 2016 , 13, 278	10.1	17
115	Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. <i>Journal of Neurology</i> , 2016 , 263, 1626-32	5.5	29
114	Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 862-72	5	51
113	Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies. <i>Therapeutic Advances in Neurological Disorders</i> , 2016 , 9, 336-43	6.6	12
112	Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation. <i>Journal of Neuroinflammation</i> , 2016 , 13, 48	10.1	53
111	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016 , 79, 206-16	9.4	219
110	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2016 , 387, 1075-1084	4.0	271
109	Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis. <i>Neurotherapeutics</i> , 2016 , 13, 47-57	6.4	36
108	<i>Pseudomonas aeruginosa</i> and Its Bacterial Components Influence the Cytokine Response in Thymocytes and Splenocytes. <i>Infection and Immunity</i> , 2016 , 84, 1413-1423	3.7	12
107	Disease-modifying therapies and infectious risks in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2016 , 12, 217-33	15	148
106	Pushing Forward: Remyelination as the New Frontier in CNS Diseases. <i>Trends in Neurosciences</i> , 2016 , 39, 246-263	13.3	64
105	Predicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic Neuritis. <i>PLoS ONE</i> , 2016 , 11, e0164099	3.7	3
104	Redox Events As Modulators of Pathology and Therapy of Neuroinflammatory Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2016 , 4, 63	5.7	5
103	Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling. <i>Journal of Neuroinflammation</i> , 2016 , 13, 143	10.1	16
102	CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation. <i>PLoS ONE</i> , 2016 , 11, e0146503	3.7	15
101	Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with <i>Candida utilis</i> Expressing the Immunogenic MOG35-55 Peptide. <i>PLoS ONE</i> , 2016 , 11, e0155082	3.7	10
100	Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectives. <i>Current Opinion in Neurology</i> , 2016 , 29, 199-204	7.1	31
99	Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. <i>JAMA Neurology</i> , 2016 , 73, 1089-98	17.2	67

98	Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system. <i>Journal of the Peripheral Nervous System</i> , 2016 , 21, 85-94	4.7	8
97	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1005-15	5.5	157
96	Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. <i>Journal of Neurology</i> , 2016 , 263, 1418-26	5.5	32
95	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1386-1396	5	83
94	Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of Chinese restaurant syndrome? <i>Journal of Neurology</i> , 2016 , 263, 1027-1028	5.5	2
93	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. <i>Neurology</i> , 2016 , 87, 1985-1992	6.5	38
92	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. <i>Trials</i> , 2016 , 17, 345	2.8	19
91	Activation of Wnt signaling promotes hippocampal neurogenesis in experimental autoimmune encephalomyelitis. <i>Molecular Neurodegeneration</i> , 2016 , 11, 53	19	9
90	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. <i>Neurology</i> , 2016 , 87, 978-87	8.5	78
89	A phase IIa randomized clinical study testing GNBAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up. <i>Journal of Neuroimmunology</i> , 2015 , 285, 68-70	3.5	33
88	Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 406-408	4	7
87	Oligodendroglial maturation is dependent on intracellular protein shuttling. <i>Journal of Neuroscience</i> , 2015 , 35, 906-19	6.6	28
86	Fingolimod induces the transition to a nerve regeneration promoting Schwann cell phenotype. <i>Experimental Neurology</i> , 2015 , 271, 25-35	5.7	34
85	PML: The Dark Side of Immunotherapy in Multiple Sclerosis. <i>Trends in Pharmacological Sciences</i> , 2015 , 36, 799-801	13.2	27
84	Axonal damage in papilledema linked to idiopathic intracranial hypertension as revealed by multifocal visual evoked potentials. <i>Clinical Neurophysiology</i> , 2015 , 126, 2040-1	4.3	9
83	Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. <i>Journal of Neurology</i> , 2015 , 262, 2466-71	5.5	4
82	Genome-wide significant association with seven novel multiple sclerosis risk loci. <i>Journal of Medical Genetics</i> , 2015 , 52, 848-55	5.8	27
81	The neutralizing antibody GNBAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1200-3	5	38

80	No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. <i>Neurology</i> , 2015 , 85, 1694-701	6.5	39
79	Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. <i>JAMA Neurology</i> , 2015 , 72, 1458-65	17.2	90
78	Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography. <i>Neurology</i> , 2015 , 85, 521-7	6.5	18
77	Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. <i>Neurology</i> , 2015 , 85, 610-8	6.5	40
76	Hyperglycemia and PPAR α Antagonistically Influence Macrophage Polarization and Infarct Healing After Ischemic Stroke. <i>Stroke</i> , 2015 , 46, 2935-42	6.7	22
75	A phase IIa randomised clinical study of GNBAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 885-93	5	40
74	Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1036-44	5	50
73	Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 22-34	5	78
72	Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 43-55	5.3	59
71	Immunoglobulins stimulate cultured Schwann cell maturation and promote their potential to induce axonal outgrowth. <i>Journal of Neuroinflammation</i> , 2015 , 12, 107	10.1	11
70	Macrophage-derived osteopontin induces reactive astrocyte polarization and promotes re-establishment of the blood brain barrier after ischemic stroke. <i>Glia</i> , 2015 , 63, 2198-207	9	70
69	IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties. <i>Trends in Pharmacological Sciences</i> , 2015 , 36, 419-21	13.2	12
68	Redox-regulated fate of neural stem progenitor cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2015 , 1850, 1543-54	4	24
67	Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015 , 72, 756-63	17.2	163
66	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1013-24	5	181
65	Risk evaluation and monitoring in multiple sclerosis therapeutics. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1306-11	5	21
64	IVIg regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). <i>Journal of Neuroimmunology</i> , 2014 , 274, 225-9	3.5	24
63	Thymic epithelium determines a spontaneous chronic neuritis in Icam1(tm1Jcgr)NOD mice. <i>Journal of Immunology</i> , 2014 , 193, 2678-90	5.3	15

62	Immune regulation of multiple sclerosis. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 3-14</i>	3	22
61	Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. <i>Lancet Neurology, The, 2014, 13, 257-67</i>	24.1	156
60	Alemtuzumab: the advantages and challenges of a novel therapy in MS. <i>Neurology, 2014, 83, 87-97</i>	6.5	35
59	Interferon β 1a for multiple sclerosis: old drug, new clothes. <i>Lancet Neurology, The, 2014, 13, 638-9</i>	24.1	3
58	FoxP3+ regulatory T cells determine disease severity in rodent models of inflammatory neuropathies. <i>PLoS ONE, 2014, 9, e108756</i>	3.7	15
57	Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis Journal, 2014, 20, 882-8</i>	5	13
56	Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. <i>Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1183-9</i>	5.5	59
55	Subtle retinal pathology in amyotrophic lateral sclerosis. <i>Annals of Clinical and Translational Neurology, 2014, 1, 290-7</i>	5.3	41
54	Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia. <i>Neurology, 2014, 83, 2153-7</i>	6.5	20
53	Atacept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. <i>Lancet Neurology, The, 2014, 13, 353-63</i>	24.1	212
52	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. <i>Multiple Sclerosis Journal, 2013, 19, 1074-83</i>	5	72
51	Plasma exchange: are bigger studies necessarily better?. <i>Nature Reviews Neurology, 2012, 8, 410-410</i>	15	
50	Volume transmission-mediated encephalopathies: a possible new concept?. <i>Archives of Neurology, 2012, 69, 315-21</i>		4
49	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. <i>Lancet, The, 2012, 380, 1819-28</i>	40	834
48	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. <i>Lancet, The, 2012, 380, 1829-39</i>	40	827
47	Advances in the management of multiple sclerosis-related spasticity. <i>Expert Review of Neurotherapeutics, 2012, 12, 1</i>	4.3	9
46	Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis. <i>Expert Review of Clinical Pharmacology, 2012, 5, 649-65</i>	3.8	6
45	Vaccination against infection in patients with multiple sclerosis. <i>Nature Reviews Neurology, 2012, 8, 143-54</i>	5.1	58

44	Guillain-Barré syndrome. <i>New England Journal of Medicine</i> , 2012 , 366, 2294-304	59.2	827
43	Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. <i>Clinical Immunology</i> , 2012 , 142, 15-24	9	76
42	Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1466-71	5	47
41	G15 Switch of cerebral A1 adenosine receptor radioligand binding during phenocconversion of Huntington disease: a PET study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, A31.1-A315.5		
40	Novel treatment for immune neuropathies on the horizon. <i>Journal of the Peripheral Nervous System</i> , 2011 , 16, 75-83	4.7	6
39	Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria. <i>Lancet Neurology, The</i> , 2011 , 10, 293-5	24.1	21
38	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011 , 476, 214-9	50.4	1948
37	CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 151-6	5	35
36	Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. <i>Archives of Neurology</i> , 2011 , 68, 1428-31		24
35	Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2010 , 362, 402-15	59.2	1686
34	Atacicept: targeting B cells in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2010 , 3, 205-16	6.6	100
33	Development of oral cladribine for the treatment of multiple sclerosis. <i>Journal of Neurology</i> , 2010 , 257, 163-70	5.5	30
32	Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. <i>Lancet Neurology, The</i> , 2009 , 8, 987-97	24.1	279
31	High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 291-309	4	18
30	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISE study): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2009 , 374, 1503-11	40	475
29	Pathogenesis and treatment of immune-mediated neuropathies. <i>Therapeutic Advances in Neurological Disorders</i> , 2009 , 2, 261-81	6.6	38
28	Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. <i>Lancet Neurology, The</i> , 2008 , 7, 136-44	24.1	505
27	The cyclin-dependent kinase inhibitor p57kip2 is a negative regulator of Schwann cell differentiation and in vitro myelination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 8748-53	11.5	50

26	Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. <i>Journal of Neurology</i> , 2008 , 255, 480-7	5.5	58
25	Advances in the understanding of the mechanism of action of IVIg. <i>Journal of Neurology</i> , 2008 , 255 Suppl 3, 3-6	5.5	92
24	Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. <i>Journal of Neurology</i> , 2007 , 254, 827-37	5.5	45
23	Impact of HMG-CoA reductase inhibition on brain pathology. <i>Trends in Pharmacological Sciences</i> , 2007 , 28, 342-9	13.2	52
22	Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. <i>Lancet, The</i> , 2007 , 370, 389-97	40	417
21	Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. <i>Neurology</i> , 2006 , 67, 1242-9	6.5	601
20	The pentapeptide QYNAD does not inhibit neuronal network activity. <i>Canadian Journal of Neurological Sciences</i> , 2005 , 32, 344-8	1	6
19	Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". <i>Annals of Neurology</i> , 2005 , 58, 840-6	9.4	4020
18	Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. <i>Neurology</i> , 2005 , 64, 1336-43	4.3	250
17	Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. <i>Archives of Neurology</i> , 2005 , 62, 1620-3		99
16	Immune mechanisms in neurological disease 2002 , 1501-1526		1
15	Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. <i>Neurology</i> , 2002 , 59, 909-13	6.5	136
14	Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. <i>Lancet, The</i> , 2002 , 360, 2018-25	40	728
13	Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. <i>Annals of Neurology</i> , 2001 , 50, 121-7	9.4	5368
12	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. <i>Lancet, The</i> , 2001 , 357, 1576-82	40	884
11	The role of interferon-gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system. <i>Annals of Neurology</i> , 1990 , 27, 247-57	9.4	103
10	Macrophages but not Schwann cells express Ia antigen in experimental autoimmune neuritis. <i>Annals of Neurology</i> , 1990 , 28, 70-7	9.4	44
9	Substance P, the immune system and inflammation. <i>International Reviews of Immunology</i> , 1989 , 4, 229-49.	16	29

8	The blood-nerve barrier in Wallerian degeneration: a sequential long-term study. <i>Muscle and Nerve</i> , 1989 , 12, 627-35	3.4	65
7	Suppression of experimental autoimmune neuritis by the oxygen radical scavengers superoxide dismutase and catalase. <i>Annals of Neurology</i> , 1988 , 23, 453-60	9.4	74
6	Immune mechanisms in inflammatory polyneuropathy. <i>Annals of the New York Academy of Sciences</i> , 1988 , 540, 122-61	6.5	76
5	Suppression of P2-T-cell line mediated experimental autoimmune neuritis by interleukin-2 receptor blockade. <i>Annals of the New York Academy of Sciences</i> , 1988 , 540, 563-5	6.5	1
4	Adoptive transfer experimental autoimmune encephalomyelitis. Evidence for central nerve and spinal root dysfunction. <i>Annals of the New York Academy of Sciences</i> , 1988 , 540, 738-40	6.5	
3	Substance P and astrocytes: stimulation of the cyclooxygenase pathway of arachidonic acid metabolism. <i>FASEB Journal</i> , 1988 , 2, 48-51	0.9	87
2	Chemically modified low density lipoproteins as inducers of enzyme release from macrophages. <i>FEBS Letters</i> , 1985 , 186, 211-4	3.8	27
1	Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7. <i>FEBS Letters</i> , 1983 , 160, 209-12	3.8	65